---
title: "Shanghai Shen Lian Biomedical Corporation (688098.SH)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/688098.SH.md"
symbol: "688098.SH"
name: "Shanghai Shen Lian Biomedical Corporation"
industry: "Pharmaceuticals"
datetime: "2026-05-20T15:30:53.004Z"
locales:
  - [en](https://longbridge.com/en/quote/688098.SH.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/688098.SH.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/688098.SH.md)
---

# Shanghai Shen Lian Biomedical Corporation (688098.SH)

## Company Overview

Shanghai Shen Lian Biomedical Corporation engages in the research, development, production, and sale of veterinary biological products in China. It develops synthetic peptide vaccines to treat foot-and-mouth diseases. The company was founded in 2001 and is headquartered in Shanghai, China.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | CN Market |
| Website | [www.slbio.com.cn](https://www.slbio.com.cn) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:09.000Z

**Overall: C (0.58)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 153 / 215 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -7.47% |  |
| Net Profit YoY | 57.84% |  |
| P/B Ratio | 2.52 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 3509023757.79 |  |
| Revenue | 272607775.01 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -1.37% | D |
| Profit Margin | -7.06% | D |
| Gross Margin | 63.25% | A |
| Revenue YoY | -7.47% | D |
| Net Profit YoY | 57.84% | B |
| Total Assets YoY | -1.97% | D |
| Net Assets YoY | -1.64% | D |
| Cash Flow Margin | -112.27% | E |
| OCF YoY | -7.47% | D |
| Turnover | 0.18 | D |
| Gearing Ratio | 8.71% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Shanghai Shen Lian Biomedical Corporation",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-7.47%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "57.84%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "2.52",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "3509023757.79",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "272607775.01",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-1.37%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "-7.06%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "63.25%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "-7.47%",
          "rating": "D"
        },
        {
          "name": "Net Profit YoY",
          "value": "57.84%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "-1.97%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "-1.64%",
          "rating": "D"
        },
        {
          "name": "Cash Flow Margin",
          "value": "-112.27%",
          "rating": "E"
        },
        {
          "name": "OCF YoY",
          "value": "-7.47%",
          "rating": "D"
        },
        {
          "name": "Turnover",
          "value": "0.18",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "8.71%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -178.96 | 216/215 | - | - | - |
| PB | 2.48 | 116/215 | 3.11 | 2.68 | 2.06 |
| PS (TTM) | 12.63 | 194/215 | 14.56 | 13.11 | 9.87 |
| Dividend Yield | 0.00% | - | 0.60% | 0.59% | 0.58% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Allist (688578.SH) | A | A | B | A | B | A |
| 02 | Xingqi Pharmaceutical (300573.SZ) | A | A | A | A | B | A |
| 03 | Hengrui Pharma (600276.SH) | A | B | C | A | B | B |
| 04 | Yunnan Baiyao (000538.SZ) | B | C | B | B | C | B |
| 05 | Haisco (002653.SZ) | A | A | B | B | B | B |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/688098.SH/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/688098.SH/norm.md)
- [Related News](https://longbridge.com/en/quote/688098.SH/news.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**